Page 195 - Genentech News Today

/PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the VENTANA PD-L1 (SP263)...

The French drug company got the nod for a hemophilia treatment.

Supporters have helped the councilman amass nearly $1.5 million, allowing him to hire a legal team that has won courtroom victories for Google and Kaiser Permanente.

BLA submission initiated for afami-cel, with aim to complete in mid-2023; afami-cel has the potential to be the first marketed engineered TCR T-cell therapy for a solid tumor52% (13/25) response rate

North Bethesda, Maryland USA (PRWEB) March 06, 2023 -- For the first time in the history of the ISPE Facility of the Year Awards (FOYA) program, the

Greater disease activity was not evident in MS patients given a next Ocrevus infusion at times beyond the recommended every six months.

A daily 40-mg dose of atorvastatin for 12 months significantly cut incident cardiac dysfunction in patients with lymphoma receiving anthracycline treatment.

NEW ORLEANS — In the STOP-CA trial, prophylactic atorvastatin therapy reduced the occurrence of anthracycline-associated left ventricular dysfunction at 12 months among patients who underwent treatment for Hodgkin and non-Hodgkin lymphoma.“Anthracyclines are a standard chemotherapy drug used in the treatment of breast cancer and lymphoma. Anthracyclines are prescribed to more than 1

The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term.

With the 2023 Texas State of Reform Health Policy Conference coming up next week, we wanted to share the list of organizations that will be attending our event. It's an impressive list and one that we're honored to host and convene on March 9th!